Rocket Pharmaceuticals (RCKT) rose in afternoon trading on Thursday after Goldman Sachs upgraded the gene therapy developer to Neutral from Sell, citing the latest updates on RP-A501, its experimental therapy for a rare disorder called Danon disease.
As part of
